Attached files
file | filename |
---|---|
EX-10.4 - EX-10.4 - Xenon Pharmaceuticals Inc. | xene-ex104_122.htm |
EX-31.1 - EX-31.1 - Xenon Pharmaceuticals Inc. | xene-ex311_9.htm |
EX-31.2 - EX-31.2 - Xenon Pharmaceuticals Inc. | xene-ex312_10.htm |
EX-32.1 - EX-32.1 - Xenon Pharmaceuticals Inc. | xene-ex321_12.htm |
10-K - 10-K - Xenon Pharmaceuticals Inc. | xene-10k_20201231.htm |
EX-10.33 - EX-10.33 - Xenon Pharmaceuticals Inc. | xene-ex1033_6.htm |
EX-32.2 - EX-32.2 - Xenon Pharmaceuticals Inc. | xene-ex322_7.htm |
|
|
|
|
|
|
|
|
|
KPMG LLP |
|
|
|
|
|
|
Chartered Accountants |
|
|
|
|
|
|
PO Box 10426 777 Dunsmuir Street |
|
|
|
|
|
|
Vancouver BC V7Y 1K3 |
|
|
|
|
|
|
Telephone (604) 691-3000 |
|
|
|
|
|
|
Fax (604) 691-3031 |
|
|
|
|
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
Xenon Pharmaceuticals Inc.
We consent to the incorporation by reference in the registration statements (Nos. 333-199860, 333-202765, 333-210050, 333-216543, 333-223497, 333-230103, 333-233758, 333-237036, and 333-238895) on Form S-8 and (No. 333-238896) on Form S-3 of Xenon Pharmaceuticals Inc. of our report dated March 1, 2021, with respect to the consolidated balance sheets of Xenon Pharmaceuticals Inc. as of December 31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2020, and the related notes (collectively, the “consolidated financial statements”), which report appears in the December 31, 2020 annual report on Form 10-K of Xenon Pharmaceuticals Inc.
/s/ KPMG LLP
Chartered Professional Accountants
March 1, 2021
Vancouver, Canada
KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. KPMG Canada provides services to KPMG LLP.